Browsing Tag
RNA interference
3 posts
How the RNA therapeutics sector is shifting focus toward manufacturing scalability challenges
Explore why RNA therapeutics companies are increasingly prioritizing manufacturing scalability, stereochemical control, and industrial RNA production efficiency.
Can RNA interference expand beyond rare diseases through Tenaya–Alnylam cardiovascular research? (NASDAQ: ALNY, NASDAQ: TNYA)
Tenaya Therapeutics and Alnylam Pharmaceuticals partner to discover RNAi drug targets for cardiovascular disease. Read what this biotech deal could mean.
Why Vir Biotechnology’s tobevibart and elebsiran combo may signal a breakthrough in hepatitis delta treatment
Vir Biotechnology’s hepatitis delta therapy shows 66% RNA clearance at 48 weeks. Find out why this could redefine treatment ahead of 2027 trial results.